Drug Trial Radar · NCT05835752
The Safety, Tolerability and Pharmacokinetic Study of RAY1225
Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
May 18, 2023
Primary completion
Mar 1, 2024
Study completion Mar 23, 2024
Sponsor
- Lead sponsor
- Guangdong Raynovent Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of RAY1225
Conditions
- Obese
- Healthy
Interventions
RAY1225Drug
Administered SC
PlaceboDrug
Administered SC
RAY1225Drug
Administered SC
PlaceboDrug
Administered SC
RAY1225Drug
Administered SC
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE)Time frame: Baseline through Day 29 (Part A)
- Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE)Time frame: Baseline through Day 64 (QW,Part B&C);baseline through Day 71 (Q2W,Part B&C)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanfang Hospital,South Medical Hospital
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.